$MSLE News

Satellos to Participate in Upcoming Investor Conferences

Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24

Satellos Granted Composition of Matter Patent for Forazapadin

Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform

Satellos Bioscience Completes Enrollment in Phase 2 Basecamp Trial

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age

Satellos Receives FDA Clearance For FSHD Investigational New Drug Application

Satellos Receives FDA Clearance to Study Forazapadin in FSHD

Satellos stock jumps after FDA clears FSHD trial for forazapadin

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy

Satellos to Present at the 31st Annual Congress of the World Muscle Society

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Satellos to Participate in Upcoming Investor Conferences

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate

Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update

HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18